前列腺癌治疗后尿道并发症的长期发病率:基于人群分析
基于阿尔伯塔癌症登记库2002至2021年前列腺癌患者数据,评估不同治疗方式后尿道并发症的长期发病率。中位随访79个月,47,387例患者中3,140例发生尿道并发症。联合治疗模式15年发生率最高(EBRT+Cryo 42%,EBRT+BT 26%,RP+EBRT 22%),观察/药物治疗(8%)和根治性前列腺切除术(9%)最低。
要点
- 联合治疗模式尿道并发症15年发生率最高,达22%–42%。
- 观察/药物治疗和根治性前列腺切除术并发症风险最低(8%–9%)。
- 根治性前列腺切除术后并发症10年内趋于稳定,其他治疗持续累积。
核心结论
- 前列腺癌各种治疗方式均存在长期尿道并发症风险,联合治疗模式风险显著增高。
- 观察和根治性前列腺切除术尿道并发症风险最低,手术并发症出现较早且随时间稳定。
研究设计与样本
- 基于人群的回顾性队列研究,纳入阿尔伯塔癌症登记库2002至2021年诊断为前列腺癌的男性。
- 共47,387例患者,中位年龄66岁(IQR 14),中位随访79个月(25百分位36,75百分位140)。
- 尿道并发症定义为治疗后>30天发生狭窄、瘘或需尿道操作。
- 患者分为8个治疗组:RP、EBRT、BT、Cryo、RP+EBRT、EBRT+BT、Cryo+EBRT、MT/O。
- 使用Cox回归比较组间尿道并发症风险。
主要发现
- 3,140例患者发生尿道并发症。
- 多变量Cox回归显示年龄(P < .001)、分期(P = .001)和治疗方式(P < .001)与尿道并发症独立相关。
- 与MT/O相比,大多数治疗方式与并发症发生相关。
- 15年尿道并发症发生率:EBRT+Cryo 42%、EBRT+BT 26%、RP+EBRT 22%、MT/O 8%、RP 9%。
- RP后并发症10年趋于稳定,其他方式随时间持续累积。
关键数值与推荐
- 尿道并发症定义:治疗后>30天出现狭窄、瘘或尿道操作。
- 15年尿道并发症发生率最高为EBRT+Cryo(42%),最低为MT/O(8%)和RP(9%)。
- 多变量分析中年龄、分期、治疗方式均与尿道并发症独立相关(P < .001、P = .001、P < .001)。
临床怎么用
- 前列腺癌治疗决策时应告知患者长期尿道并发症风险,尤其联合治疗模式。
- 对接受联合治疗的患者应长期随访尿道并发症,因风险持续累积。
- 根治性前列腺切除术后尿道并发症多在10年内出现并趋于稳定。
局限性
- 基于登记库的回顾性研究,可能存在编码偏倚和混杂因素。
- 尿道并发症定义依赖操作记录,可能低估无症状或未就诊病例。
- 未报告各治疗组的具体样本量和并发症亚型分布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite robust 15-year cancer-specific survival for localized prostate cancer (CaP), long-term urethral complications after treatment are sparsely reported. Our objective is to assess the long-term incidence of urethral complications after CaP treatment. MATERIALS AND METHODS: Men with the diagnosis of CaP from 2002 to 2021 in the Alberta Cancer Registry were evaluated for complications using the Discharge Abstract Database and the National Ambulatory Care Reporting System. Urethral complications were defined as development of stenosis, fistula, or a urethral procedure > 30 days after treatment. Patients were allocated into 8 treatment groups, radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), cryotherapy (Cryo), RP + EBRT, EBRT + BT, Cryo + EBRT, or medical treatment/observation (MT/O). Urethral complications were compared between groups using Cox regression. RESULTS: A total of 47,387 patients were identified with a median age of 66 years (IQR 14). At a median follow-up of 79 months (25th percentile = 36, 75th percentile = 140), 3140 patients developed urethral complications. On multivariable Cox regression, age (P < .001), stage (P = .001), and treatment modality (P < .001) were independently associated with urethral complications. Most treatment modalities were associated with development of complications when compared with MT/O. The 15-year incidence of urethral complications was the highest for combined modalities. EBRT + Cryo (42%), EBRT + BT (26%), and RP + EBRT (22%) were at the highest risk while MT/O (8%) and RP (9%) were at the lowest. Complications after RP plateaued at 10 years, whereas other modalities continued to accumulate complications over time. CONCLUSIONS: Patients undergoing CaP treatment are at a risk of developing urethral complications in the long term regardless of treatment modality. However, combined modalities pose a heightened risk while observation and radical prostatectomy have the lowest with complications from surgery appearing earlier and stabilizing over time.
引用
- Calvo CI, Rourke KF. Delineating the Long-Term Incidence of Urethral Complications After Prostate Cancer Treatment: A Population-Based Analysis. J Urol. 2026. PMID: 42566775. doi:10.1097/JU.0000000000005222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。